

Mediclinic International plc  
(Incorporated in England and Wales)  
Company Number: 08338604  
LSE Share Code: MDC  
JSE Share Code: MEI  
NSX Share Code: MEP  
ISIN: GB00B8HX8Z88  
LEI: 2138002S5BSBIZTD5I60  
(“**Mediclinic**”, or the “**Company**”, or the “**Group**”)

28 June 2022

## **BROAD-BASED BLACK ECONOMIC EMPOWERMENT ACT: ANNUAL COMPLIANCE REPORT**

In accordance with the JSE Limited Listings Requirements, notice is hereby given that the Company’s annual broad-based black economic empowerment compliance report (“**compliance report**”) in terms of section 13G (2) of the South African Broad-Based Black Economic Empowerment Act, No. 53 of 2003, as amended (the “**B-BBEE Act**”), has been submitted to the Broad-Based Black Economic Empowerment Commission (the “**B-BBEE Commission**”). The compliance report is available on Mediclinic’s website at <https://www.mediclinic.com/en/sustainable-development.html>.

The compliance report relates to the Group’s South African operations and presents an assessment of the broad-based black economic empowerment status of Mediclinic International (RF) (Pty) Ltd, a wholly owned subsidiary of the Company, and its subsidiaries which include Mediclinic Southern Africa (Pty) Ltd.

### **About the B-BBEE Act**

The B-BBEE Act was enacted to establish a legislative framework for the promotion of broad-based black economic empowerment in South Africa. It covers aspects such as ownership, management control, skills development, enterprise and supplier development and socio-economic development. Although compliance with the B-BBEE Act and the Codes of Good Practice issued in terms thereof is voluntary, an obligation was introduced by way of an amendment to the B-BBEE Act in 2013, which became effective in June 2016, requiring a public company, listed on the Johannesburg Stock Exchange (“**JSE**”), to submit its annual compliance report to the B-BBEE Commission, to load its compliance report on its website and to publish a SENS announcement confirming the aforementioned steps taken.

### **About Mediclinic International plc**

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case clinics and 20 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 20 outpatient clinics with around 1 000

inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ('LSE') in the UK, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the UK and listed on the LSE.

For further information, please contact:

**Company Secretary, Link Company Matters Limited**

Caroline Emmet  
+44 (0)333 300 1930

**Investor queries**

James Arnold, Head of Investor Relations, Mediclinic International plc  
+44 (0)20 3786 8181  
[ir@mediclinic.com](mailto:ir@mediclinic.com)

**Media queries**

FTI Consulting  
Ben Atwell/Ciara Martin - UK  
+44 (0)20 3727 1000  
Sherryn Schooling - South Africa  
+27 (0)21 487 9000

**Registered address:** 6<sup>th</sup> Floor, 65 Gresham Street, London, EC2V 7NQ, UK

**Website:** [www.mediclinic.com](http://www.mediclinic.com)

**Joint corporate brokers:** Morgan Stanley & Co International plc and UBS Investment Bank

**JSE sponsor (South Africa):** Rand Merchant Bank (A division of FirstRand Bank Limited)

**NSX sponsor (Namibia):** Simonis Storm Securities (Pty) Ltd